AKST4290 is an orally administered small molecule that inhibits the interaction of CCL11, an inflammatory protein that has been implicated in a number of age-related diseases, with its G protein-coupled receptor CCR3. ALK4290 has been shown to be neuroprotective in animals, and was well tolerated in Phase 1 Clinical trials in healthy volunteers. Clinical trials in patients with Age Related Macular Degeneration (wet AMD), the leading cause of blindness in adults, are currently ongoing, and studies in additional indications are being planned. AKST4290 is the subject of a number of issued patents and patent applications filed throughout the world.